Creating a new imaging tool to detect specific immune cells in Alzheimer's disease

Development of an amphiphilic PET probe to detect CD206+ microglia/macrophages in Alzheimer's disease

NIH-funded research Massachusetts General Hospital · NIH-10949738

This study is testing a new imaging tool that helps doctors see specific immune cells in the brains of people with Alzheimer's, which could help us understand how these cells affect the disease and how well new treatments might work.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10949738 on NIH RePORTER

What this research studies

This research focuses on developing a novel imaging probe that can identify CD206+ microglia and macrophages in the brains of Alzheimer's disease patients. By using a non-invasive method, the study aims to differentiate between the protective and harmful roles of these immune cells in Alzheimer's pathology. The approach involves creating a probe that can cross the blood-brain barrier and specifically target the anti-inflammatory macrophages, which are crucial for understanding disease progression and treatment response. This could provide valuable insights into the effectiveness of new therapies aimed at modifying immune cell behavior in Alzheimer's.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.

Not a fit: Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment strategies for Alzheimer's disease by enabling better monitoring of immune cell activity in the brain.

How similar studies have performed: Previous research has shown promise in using imaging techniques to study immune responses in neurological conditions, but this specific approach targeting CD206+ cells is novel.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's DiseaseAlzheimer's disease brainAlzheimer's disease model
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.